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Abstract 
The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events 
and/or pregnancy loss in the presence of persistent laboratory evidence for 
antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid 
antibodies include laboratory assays that detect anticardiolipin antibodies, lupus 
anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly 
focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on 
the pathogenic significance of IgA aPL  
In this review we aimed to summarize and analyse the evidence published in the 
literature on the prevalence and the clinical significance of IgA aPL. 
Introduction 
 Antiphospholipid antibodies (aPL) are a heterogeneous Group of circulating 
autoantibodies that are found in the sera of patients with autoimmune and infectious 
diseases, the antiphospholipid syndrome (APS), and even in healthy subjects [1, 2]. The 
APS is characterized by the association of raised levels of circulating aPL with a spectrum 
of clinical manifestations such as arterial and venous thrombosis, recurrent pregnancy loss, 
and thrombocytopenia [3].  
Testing for APS has traditionally included assays for lupus anticoagulant (LAC) and 
anticardiolipin antibodies (aCL), and anti-2 glycoprotein I (anti-2GPI). However, recent 
evidence gathered through the last years of work suggests that other aPL specificities can 
also be play a role in the pathogenesis of the syndrome [4-7].   
 Most studies on aPL have mainly focused on the estimation of the IgG and IgM 
isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In 
studies where IgA aCL and/or anti-2GPI were measured, conflicting findings of their 
prevalence and clinical relevance have been reported. In fact, in addition to thromboembolic 
manifestations and intrauterine foetal loss, other symptoms such as livedo reticularis, skin 
ulcers, headaches, cognitive disfunction, transient isquemic atacks or heart valve disease 
have also been found in association with IgA aPL, [8-11].  
Raised levels of IgA aPL have not been included in the classification criteria for the 
APS [12, 13], being the main reason for their exclusion that these particular assays are not 
yet fully standardized. This issue also makes it very difficult to compare studies from 
different laboratories [14-16]. Secondly, there is limited availability of appropriate standards 
tests and no universal cut-off level accepted despite attempts at International 
standardization of results. Inter-laboratory variation of results using commercial kits helps to 
create significant confusion for physicians where tests may be positive in one laboratory 
and negative in another. And finally, differences in the ethnic composition of the populations 
studied could also play an important role in the overall confusion [17]. 
Generally speaking, the aCL test is positive in about 80% of patients with APS, being 
the LAC the only positive test in about 20%. Around 60% of the APS cases are positive for 
both. Anti-2GPI is associated with thrombosis and other features of APS. Indeed, in few 
patients with clinical features of APS, IgA anti-2GPI has been reported as the sole 
antibody detected. Several authors have suggested that testing for new specifities may help 
to identify additional patients with clinical suspicion of APS who do not meet the current 
criteria for APS [18, 19]. 
The purpose of this review is to try to summarize and analyse the evidence 
published in the literature on the prevalence and the clinical significance of IgA aPL. 
 
Methods 
 Using MEDLINE, Cochrane and OVID databases, we systematically reviewed all 
publications from January 1990 until April 2012, using the MESH strategy for the term 
“Immunoglobulin A” with the AND function and “antiphospholipid” and all the heading. In a 
second step we added the term “stroke” and “cardiovascular disease” to analyse the 
relationship with these antibodies. All articles referred to pediatric medicine and those were 
only the abstract was available were excluded. The search was amplified by a manual 
review of the selected article references.  
   
Results 
Thirty-one relevant articles were selected. These were then divided into 3 subgroups: 
(1) studies which were performed in an autoimmune population and showed usefulness of 
IgA aPL testing; (2) studies in which their authors showed no usefulness for IgA testing, and 
(3) studies of IgA aPL in other non-autoimmune disorders. We analysed the prevalence of 
IgA aCL and anti-2GPI, and the association with clinical manifestations, as the sole 
antibody or in combination with other aPL. 
 The studies that reported positive results in autoimmune population are shown in 
Table 1. Excluding case-reports, a highly variable prevalence of IgA aPL has been 
reported, being the highest of 78% for IgA aCL in a series of 33 APS patients [20], and  
72% for IgA anti-2GPI in a cohort of 67 APS patients [21].  
In addition to thrombosis and pregnancy morbidity, associations between high titers 
of IgA APL and skin ulcers [22], cognitive impairment [23], Raynaud [24], 
trombocitopenia[20], heart valve disease [20], livedo [20], and epilepsia [20], celiac disease 
[25], as well as with autoimmune hepatitis [26] were also reported.  
Only 6 studies found a statistically significant association between different APS-
related clinical manifestations and IgA aPL in the absence of other antibodies/isotypes. 
Kumar et al [22] showed IgA anti-2GPI alone in 4/5 cases with pregnancy morbidity. 
Similarly, Lee et al [18] showed that 44% had IgA anti-2GPI without other aPL, in a series 
of patients with unexplained pregnancy loss. Shen et al25 highlighted that 7% of patients 
with connective tissue disorders had IgA anti-2GPI in the absence of other markers of 
APS, and their presence was significantly associated with arterial thrombosis. Diri et al [27] 
showed IgA anti-2GPI as the sole aPL in 2/8 cases with skin ulcers. Finally, Lakos et al 
[20] reported a prevalence of 5.7% for isolated IgA anti-2GPI in patients with APS-related 
features. More recently, Sweiss et al [28] reported that isolated IgA anti-2GPI was 
associated with an increased risk of thromboembolic events in the 56 patients with and 
without SLE (p=0.018, OR 2.79 [95%CI 1.263–6.172]). Interestingly, when they restricted 
their analysis to patients with SLE, isolated IgA anti-2GPI was still associated with an 
increased risk of events (p=0.026, OR 4.28 [95%CI 1.33–13.56]). In contrast, among non-
SLE patients, isolated IgA anti-2GPI was not associated with an increased risk of 
thromboembolic events (p=0.773, OR 1.39 [95%CI 0.45–4.27]). These data suggested that 
IgA anti-2GPI may be associated with an increased risk of thromboembolic events in the 
presence, but not in the absence, of SLE. 
When analysing a cohort of 796 SLE patients, Mehrani et al [29] found that a history 
of venous thrombosis was significantly associated with IgA  anti-2GPI positivity (24.2%) as 
compared to the IgA anti-2GPI negative (15.8%) population. For the patients with IgA anti-
2GPI alone, 22.1% had venous thrombosis and 11.9% had arterial thrombosis. For IgA 
aCL alone, 11.1% had venous thrombosis and 5.35% had arterial thrombosis.  
Table 2 depicts negative studies in autoimmune populations. As previously, the 
prevalence of IgA aPL was very variable, being the lowest prevalence of 0.2% reported by 
Selva-O´Callaghan et al [30] when studying a large series of 773 patients. Most of the 
studies even reported an association between IgA aPL and thrombosis and/or pregnancy 
morbidity; when this was analyzed separately, in the absence of other aPL, the association 
was lost. In fact, Samarkos et al [31] showed that the addition of IgA aPL for the diagnosis 
of APS, not only failed to improve, but even decreased the accuracy of the test. 
More recently, Holc at al [32] in a follow-up study with carefully selected premenopausal 
Rheumatoid Arthritis females patients with initially low risk for atherosclerosis failed to 
confirm their original impression that IgA anti-2GPI might represent an independent risk 
factor for atherosclerosis. 
Table 3 shows studies on IgA aPL in the general population. Yamada et al [33] 
studied the prevalence of these antibodies in 36 pregnant women without underlying 
autoimmune disease and recurrent pregnancy loss, showing IgA anti-2GPI in 14% of 
them. Other studies have highlighted the association between atherosclerotic disease 
(stroke, acute myocardial infarction and peripheral arterial disease) and the presence of IgA 
anti-2GPI alone, in the absence of other aPL, data that needs to be confirmed by larger 
studies.  
Serrano et al [34], following prospectively a total of 148 patients on dialysis for 2 
years, reported that IgA anti-β2GPI were an independent risk factor for mortality in 
hemodialysis patients, suggesting a potential role for IgA anti-β2GPI in evaluating the 
clinical outcome of hemodialysis patients. 
 
Discussion  
Most of the clinical data that supports testing for IgA aPL is based on retrospective 
studies, case-report and case-series, making it difficult to compare these studies with each 
other due to differences in design, population studied, the non-standardised assays used 
and the different cut-off chosen. As a result and in the absence of well-designed 
prospective studies, the controversy over the usefulness of IgA aPL testing continues. 
Several studies failed to prove usefulness of adding IgA aCL and IgA anti-2GPI testing, 
either because of low prevalence of these antibodies, in most of the cases because they 
are found in association with  other aPL, and also because of the lack of improvement in 
diagnostic accuracy when routinely tested. 
However, a number of authors reported that some patients who do not meet the 
criteria for APS could benefit from being tested for IgA aPL. These reports are based on 
studies with a low level of evidence, predominantly from case-series and case-reports, 
where different not standardized assays have been used.  Although IgA aPL is detected 
alone, in most of the cases this is linked to skin ulcers, Raynaud’s, livedo or cutaneous 
vasculitis. In most cases were major APS manifestations occur (i.e. thrombosis) IgA aPL 
are usually found in association with other isotypes (i.e IgG and/or IgM).  
Some evidence for the importance of testing for IgA aPL comes from pregnancy 
morbidity studies, although, again, there are small series with controversial results.  
Finally, numerous studies show a high prevalence of IgA anti-2GPI in the general 
population with atherosclerotic disease, especially stroke. Interestingly, they did not detect 
other types of aPL neither other features of APS. The possibility of a different molecule, 
with a different domain and therefore different targets with respect to those responsible for 
the APS is still elusive.  
 
Conclusions 
To summarize, based on the data published until now, there is not enough evidence 
to recommend testing for IgA aCL and/or IgA anti-2GPI to increase the diagnostic 
accuracy of the APS. Prospective studies assessing the clinical significance of these 
antibodies are crucial to establish their clinical value. 
 
 References 
 
[1] McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of 
antiphospholipid antibodies. Advances in immunology. 1991;49:193-280. 
[2] RA Asherson RC. Anticardiolipin antibodies, chronic biologic false-positive test for 
syphilis and other antiphospholipid antibodies. In: Wallace DJ HB, Editors, editor. Dubois´s 
LE 4th ed. Philadelphia: Lea & Febiber; 1993: 233-45. 
[3] Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. 
The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 
(Baltimore). 1989;68:366-74. 
[4] Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 
glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid 
syndrome. Autoimmunity reviews. 2012. 
[5] Chamorro AJ, Marcos M, Miron-Canelo JA, Cervera R, Espinosa G. Val247Leu beta2-
glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic 
review and meta-analysis. Autoimmunity reviews. 2012. 
[6] Mirarabshahi P, Abdelatti M, Krilis S. Post-translational oxidative modification of beta2-
glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. 
Autoimmunity reviews. 2011. 
[7] Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, 
thromboembolic events and the antiphospholipid syndrome. Autoimmunity reviews. 2012. 
[8] Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, et al. Transverse myelitis in 
patients with antiphospholipid antibodies--the importance of early diagnosis and treatment. 
Clin Rheumatol. 2002;21:207-10. 
[9] Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al. Livedo reticularis is 
a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp 
Rheumatol. 2005;23:499-504. 
[10] Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN. A 
comparison of cardiac valvular involvement in the primary antiphospholipid syndrome 
versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J. 1993;125:1123-
9. 
[11] Cervera R, Conti F, Doria A, Iaccarino L, Valesini G. Does seronegative 
antiphospholipid syndrome really exist? Autoimmunity reviews. 2012;11:581-4. 
[12] Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. 
International consensus statement on preliminary classification criteria for definite 
antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 
1999;42:1309-11. 
[13] Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International 
consensus statement on an update of the classification criteria for definite antiphospholipid 
syndrome (APS). J Thromb Haemost. 2006;4:295-306. 
[14] Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the 
standardisation of the antiphospholipid antibodies. Lupus. 2009;18:913-9. 
[15] Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for 
antiphospholipid antibodies: is standardization an impossible dream? Seminars in 
thrombosis and hemostasis. 2008;34:340-6. 
[16] Lewis S, Keil LB, Binder WL, DeBari VA. Standardized measurement of major 
immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with 
antiphospholipid syndrome. Journal of clinical laboratory analysis. 1998;12:293-7. 
[17] Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the 
antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus. 2000;9:33-
41. 
[18] Samarkos M, Asherson RA, Loizou S. The clinical significance of IgA antiphospholipid 
antibodies. J Rheumatol. 2001;28:694-7. 
[19] D Ferro GV, S Basili Transient antiphospholipid antibodies positivity in patients with 
primary antiphospholipid syndrome. Lupus. 1996;5:551. 
[20] Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Isotype distribution 
and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA 
isotype. Clinical and experimental immunology. 1999;117:574-9. 
[21] Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies 
in women who experience unexplained recurrent spontaneous abortion and unexplained 
fetal death. American journal of obstetrics and gynecology. 2001;185:748-53. 
[22] Kumar S, Papalardo E, Sunkureddi P, Najam S, Gonzalez EB, Pierangeli SS. Isolated 
elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid 
syndrome: a case series of five patients. Lupus. 2009;18:1011-4. 
[23] Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and 
anticardiolipin antibodies in systemic lupus erythematosus. Arthritis and rheumatism. 
1999;42:728-34. 
[24] Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin 
and anti-beta2GPI antibodies in a large series of European patients with systemic lupus 
erythematosus. Prevalence and clinical associations. European Concerted Action on the 
Immunogenetics of SLE. Scandinavian journal of rheumatology. 1999;28:344-51. 
[25] Mankai A, Achour A, Thabet Y, Manoubia W, Sakly W, Ghedira I. Anti-cardiolipin and 
anti-beta 2-glycoprotein I antibodies in celiac disease. Pathologie-biologie. 2011. 
[26] Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, et al. 
IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. Journal of clinical 
immunology. 2008;28:501-11. 
[27] Diri E, Cucurull E, Gharavi AE, Kapoor D, Mendez EA, Scopelitis E, et al. 
Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 
glycoprotein-I is the most frequent isotype. Lupus. 1999;8:263-8. 
[28] Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al. IgA anti-beta2-
glycoprotein I autoantibodies are associated with an increased risk of thromboembolic 
events in patients with systemic lupus erythematosus. PloS one. 2010;5:e12280. 
[29] Mehrani T, Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and 
laboratory manifestations of systemic lupus erythematosus. J Rheumatol. 2011;38:64-8. 
[30] Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, 
Vilardell-Tarres M. IgA anticardiolipin antibodies--relation with other antiphospholipid 
antibodies and clinical significance. Thromb Haemost. 1998;79:282-5. 
[31] Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA 
anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus 
and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25:199-204. 
[32] Holc I, Hojs R, Cikes N, Ambrozic A, Cucnik S, Kveder T, et al. Antiphospholipid 
antibodies and atherosclerosis: insights from rheumatoid arthritis--a five-year follow-up 
study. Immunobiology. 2011;216:1331-7. 
[33] Yamada H, Tsutsumi A, Ichikawa K, Kato EH, Koike T, Fujimoto S. IgA-class anti-
beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis 
Rheum. 1999;42:2727-8. 
[34] Serrano A, Garcia F, Serrano M, Ramirez E, Alfaro FJ, Lora D, et al. IgA antibodies 
against beta2 glycoprotein I in hemodialysis patients are an independent risk factor for 
mortality. Kidney Int. 2012. 
[35] Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M. High frequency of abnormal 
levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus 
erythematosus: relationship with antiphospholipid syndrome. J Rheumatol. 1998;25:675-80. 
[36] Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Koike T. IgA class anti-
beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol. 
1998;25:74-8. 
[37] Lee SS, Cho ML, Joo YS, Kim WU, Hong YS, Min JK, et al. Isotypes of anti-beta2-
glycoprotein I antibodies: association with thrombosis in patients with systemic lupus 
erythematosus. The Journal of rheumatology. 2001;28:520-4. 
[38] Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and 
antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with 
antiphospholipid syndrome. American journal of clinical pathology. 2004;121:142-9. 
[39] Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an 
independent risk factor for thromboses. Lupus. 2008;17:996-1003. 
[40] Escalante A, Brey RL, Mitchell BD, Jr., Dreiner U. Accuracy of anticardiolipin antibodies 
in identifying a history of thrombosis among patients with systemic lupus erythematosus. 
The American journal of medicine. 1995;98:559-65. 
[41] Tajima C, Suzuki Y, Mizushima Y, Ichikawa Y. Clinical significance of immunoglobulin 
A antiphospholipid antibodies: possible association with skin manifestations and small 
vessel vasculitis. The Journal of rheumatology. 1998;25:1730-6. 
[42] Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin 
and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients 
with systemic lupus erythematosus. The American journal of the medical sciences. 
1999;318:55-60. 
[43] Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. 
Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their 
association with antiphospholipid antibody syndrome criteria: a single center study and 
literature review. The Journal of rheumatology. 2000;27:2833-7. 
[44] Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR. The 
value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome 
in systemic lupus erythematosus. J Rheumatol. 2001;28:2637-43. 
[45] Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes 
GR. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients 
with pregnancy morbidity. Annals of the rheumatic diseases. 2003;62:540-3. 
[46] Aslanidis S, Pyrpasopoulou A, Doumas M, Triantafyllou A, Chatzimichailidou S, 
Zamboulis C. Association of capillaroscopic microhaemorrhages with clinical and 
immunological antiphospholipid syndrome. Clinical and experimental rheumatology. 
2011;29:307-9. 
[47] Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. 
Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-
referent study nested within the MONICA and Vasterbotten cohort project. Stroke; a journal 
of cerebral circulation. 2000;31:1289-93. 
[48] Gonzales-Portillo F, McIntyre JA, Wagenknecht DR, Williams LS, Bruno A, Biller J. 
Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. 
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke 
Association. 2001;10:222-6. 
[49] Hsieh K, Knobl P, Rintelen C, Kyrle PA, Quehenberger P, Bialonczyk C, et al. Is the 
determination of anti-beta2 glycoprotein I antibodies useful in patients with venous 
thromboembolism without the antiphospholipid syndrome? British journal of haematology. 
2003;123:490-5. 
[50] Palomo I, Pereira J, Alarcon M, Vasquez M, Pinochet C, Velez MT, et al. Prevalence 
and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with 
venous and arterial thrombosis. Clinical rheumatology. 2004;23:129-33. 
[51] Veres K, Lakos G, Kerenyi A, Szekanecz Z, Szegedi G, Shoenfeld Y, et al. 
Antiphospholipid antibodies in acute coronary syndrome. Lupus. 2004;13:423-7. 
[52] Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG 
and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. 
Rheumatology (Oxford). 2005;44:1161-5. 
[53] Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Muhlen CA. IgA 
antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmunity reviews. 2006;6:104-
6. 
[54] Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients 
with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies 
that preferentially target domain 4 of beta2-GPI. Journal of autoimmunity. 2006;27:266-71. 
Table 1: Studies that reported positive association in autoimmune population 
Reference Study design Population 
IgA prevalence 
Clinical manifestations % Isolated IgA 
aCL anti-
2GPI 
Fanopoulos 
1998 [35] R 48 SLE 2% 58% 
Thrombosis 
PM N/A 
Tsutsumi 
1998 [36] R 124 SLE ND 25% Thrombosis N/A 
Lewis 
1998 [16] 
 
CS 43 APS ND 74% N/A N/A 
Lakos 
1999 [20] 
 
R 37 SLE              33 APS 
38% 
78% 
16%     
49% 
Deep VT 
Thrombocytopenia 
Heart Valve Disease 
Epilepsy 
Livedo 
5.7% anti-2GPI 
Diri 
1999 [27] 
 
CR 8 APS 87% 50% Stroke/TIA Transverse myelitis 25% aCL 
Sebastiani 
1999 [24] R 574 SLE 13.9% ND 
Raynaud’s 
Livedo N/A 
Hanly 
1999 [23] 
 
P 51 SLE 55% ND Cognitive dysfunction N/A 
Greco 
2000 [17] 
 
P 118 aPL 73 no aPL 
12.7% 
12% 
35.5%  
27% 
APS 
Thrombosis 
Recurrent PL 
5% aCL 
19% anti-2GPI 
Lee 
2001 [21] 
 
R 
133 PL 
48 FD 
67 APS 
11% 
2% 
16% 
44% 
38% 
72% 
PL 
FD 
APS 
100% anti-2GPI 
Lee 
2001 [37] 
 
R 270 SLE ND 34.8% Thrombosis N/A 
Lopez 
2004 [38] 
 
CS 50 SLE           140 APS N/A† N/A† 
AT 
VT 0% 
Gabeta 
2008 [26] 
 
R 192 19% 33% Autoimmune hepatitis N/A 
Shen 
2008 [39] 
 
R 472 CTD 5.5% 19.2% AT 7% anti-2GPI 
Kumar 
2009 [22] CR 5 (3 SLE) ND 100% 
PM 
Skin ulcers 80% 
Sweiss 
2010 [28] 
 
R 56 (31 SLE) ND 100% Thrombosis MIC 100% anti-2GPI 
Mankai 
2011 [25] 
 
R 63 CD 6.3% 14.3% CD diagnosis 0% aCL 7.9% anti-2GPI 
Mehrani 
2011 [29] 
 
CS 796 SLE 8.5% 20.2% Venous Thrombosis 2.4% aCL 13.1% anti-2GPI 
Under study design: R: retrospective, CS: cross-sectional, CR: case report, P: prospective. 
SLE: systemic lupus erythematosus; APS: antiphospholipid syndrome, aPL: 
antiphospholipid antibodies; CTD: connective tissue disease, CD: Celiac Disease; PM: 
pregnancy morbidity; PL: pregnancy loss; FD: fetal death; ND: not done; VT: venous 
thrombosis; AT: arterial thrombosis; N/A: not available; †OR=6 for IgA aCL and OR=14 for 
IgA anti-2GPI reported; MIC: mucosal immune system, mainly gastrointestinal and 
pulmonary system and skin.  
TABLE 2: Studies that reported no association in autoimmune populations 
Reference Study design Population 
IgA prevalence Non-associated 
clinical 
manifestations 
% isolated IgA 
 aCL anti-
2GPI 
Escalante 
1995 [40] 
 
R 113 SLE 4 PAPS N/A ND Thrombosis                     N/A 
Selva 
1998 [30]  
 
CS 
225 CTD 
153 DVT 
108 TIA 
196 PM 
0.25% ND None 0% 
Tajima 
1998 [41]  
 
R 77 CTD 61% ND Thrombocytopenia          Skin ulcers 11.6%  
Cucurull 
1999 [42] 
 
R 100 SLE 24% 19% Thrombosis 0% 
Bruce 
2000 [43]   
 
R 133 SLE ND 11% None 4.5%  
Bertolaccini 
2001 [44] 
  
CS 134 SLE 13% 6% None 3.7% aCL          0.7% anti-2GPI 
Carmo-Pereira  
2003 [45] 
   
R 
28 PAPS           
28 PM 
28 SLE 
38% 3.5% 
PAPS                                     
PM 
SLE 
2.3% aCL  
Samarkos 
2005 [31]            R 
130 SLE 
35 PAPS 
8.5% 
40% 
17.7% 
25% 
DVT                                      
Foetal loss                           
Thrombocytopenia 
0% 
Aslanidis 
2010 [46] 
 
R 
36 UCTD 
20 SLE 
24 RA 
19 APS 
43 (Other) 
N/A N/A Thrombosis  N/A 
Holc 
2011 [32] 
 
CS 68 RA ND 29.4% Atherosclerosis progression  N/A 
 
Under study design: R: retrospective, CS: cross-sectional, P: prospective. SLE: systemic 
lupus erythematosus; PAPS: primary antiphospholipid syndrome, CTD: connective tissue 
disease; DVT: deep vein thrombosis; TIA: transient ischemic attack; PM: pregnancy 
morbidity; UCTD: undifferentiated CTD; RA: rheumatoid arthritis. ND: not done; N/A: not 
available. 
Table 3: Studies on IgA aPL in the general population 
Reference Study design Population 
Prevalence IgA Clinical 
manifestations % Isolated IgA aCL anti
2GPI 
Yamada 
1999 [33]              R 36 RSA ND 14% RSA 
100% anti-
2GPI 
Ahmed 
2000 [47]                  CC 123 Stroke 4% ND None 0% 
Gonzalez-Portillo  
2001 [48]                     R 185 CVD 6.4% ND 
Stroke                                
TIA N/A 
Hsieh  
2003 [49]                       R 503 VTE ND 5.3% No thrombosis N/A 
Palomo  
2004 [50]               R 226 Thrombosis 10% 3% 
DVT                                          
AT N/A 
Veres  
2004 [51]             CS 111 ACS ND 7.2% 
Unstable angina            
STEMI                                      
Previous stroke 
3.6% anti-2GPI 
Kahles  
2005 [52]  
 
R 31 cryptic CVA 104 known CVA 1.6% 20.8% Stroke N/A 
Staub  
2006 [53]                    R 
93 stroke 
82 AMI 
73 PAD 
ND 
21% 
26% 
N/A 
Stroke                              
AMI                                   
PAD 
N/A 
Iverson   
2006 [54]                        CS 
129 APS   
382 Atherosclerosis 
9% 
48% 
1%           
33% Atherosclerosis N/A 
Serrano  
2012 [34] 
 
P 124 haemodialysis  1.6% 33.1% Mortality N/A 
Under study design: R: retrospective, CC: case control, CS: cross-sectional, P: prospective. 
RSA: recurrent spontaneous abortion; CVD: cardiovascular disease; VTE: venous 
thromboembolism; ACS: acute coronary syndrome; CVA: cerebrovascular accident; AMI: 
acute myocardial infarction; PAD: peripheral artery disease; TIA: transient ischemic attack; 
AT: arterial thrombosis; ND: not done; N/A: not available. 
  
 
